Oncolytics Biotech (ONCY) Notes Payables (2019 - 2025)

Oncolytics Biotech (ONCY) has reported Notes Payables for 7 consecutive years, with $77000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Notes Payables fell 89.02% year-over-year to $77000.0 in Q4 2025; TTM through Dec 2025 was $77000.0, a 89.02% decrease from a year earlier, with the FY2025 full-year figure at $77000.0, down 66.52% from the prior year.
• Notes Payables was $77000.0 for Q4 2025 at Oncolytics Biotech, up from $21072.4 in the prior quarter.
• Over five years, Notes Payables peaked at $3.9 million in Q3 2023 and troughed at $21072.4 in Q3 2025.
• A 5-year average of $469216.5 and a median of $113901.2 in 2023 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 10007.7% in 2023 and sank 97.37% in 2025, its largest moves.
• Over 5 years, Notes Payables stood at $44426.8 in 2021, then soared by 31.0% to $58199.5 in 2022, then soared by 6562.16% to $3.9 million in 2023, then plunged by 81.91% to $701532.2 in 2024, then plunged by 89.02% to $77000.0 in 2025.
• The last three Notes Payables figures came in at $77000.0 (Q4 2025), $21072.4 (Q3 2025), and $739033.6 (Q2 2025), per Business Quant data.